Table 3.
Standardized incidence ratios (SIRs) for lung second primary tumors (LSPTs) and esophageal second primary tumors (ESPTs)
| Author (year)ref | Observed (n) | Expected (n) | SIR (95% CI) total | SIR (95% CI) males | SIR (95% CI) females | SIR (95% CI) time frames | |
|---|---|---|---|---|---|---|---|
| LSPTs in ESCC | Ven et al. (2020) | 123 | 19 | 6.42 (5.02–8.06b) | 5.35 (3.90–7.14b) | 9.48 (6.29–13.66b) | NR |
| Chen et al. (2019) | 229 | 63 | 3.63 (3.17–4.13) | NR | NR | NR | |
| Hu et al. (2015)a | 13 | 5 | 2.79 (1.60–4.87) | NR | NR | NR | |
| Chuang et al. (2008) | 112 | 72 | 1.55 (1.28–1.87) | NR | NR |
< 6 mo: 1.47 (0.99–2.10) 6–11 mo: 0.60 (0.22–1.31) 1–4 year: 1.98 (1.43–2.67) ≥ 5 year: 1.64 (1.13–2.31) |
|
| ESPTs in LC | Abdel-Rahman and Cheung (2017) | 251 | 105 | 2.40 (1.62–3.43) |
RT: 3.60 (2.77–4.61) No RT: 2.05 (1.65–2.53) |
RT: 5.52 (3.50–8.28) No RT: NR |
1–5 year 3.09 (1.85–4.82) 5–9 year: 2.13 (0.92–4.19) ≥ 10 year: 1.17 (0.24–3.42) |
| Su et al. (2017) | 16 | 11.05 | 1.45 (0.83–2.35) | 1.55 (0.89–2.52) | 0.00 (0.00–4.90) | NR | |
| Teppo et al. (2001) | 28 | NR | NR | 1.23 (0.80–1.79) | 0.93 (0.11–3.35) | NR | |
| Chuang et al. (2010) | 159 | NR | NR |
SCC: 1.78 (1.44–2.18) SCLC: 1.46 (0.75–2.55) Adeno: 1.91 (1.26–3.09) |
SCC: 3.31 (1.81–5.56) SCLC: 3.30 (1.21–7.18) Adeno: 1.72 (0.69–3.55) |
NR | |
| Levi et al. (1999) | 5 | 2.8 | (0.6–4.4) | NR | NR | NR |
CI confidence interval, ESCC esophageal squamous cell carcinoma, ESPT esophageal second primary tumor, LC lung cancer, LSPT lung second primary tumor, RT radiotherapy, SIR standardized incidence ratio, NR not reported
aHu et al. excluded all lung squamous cell carcinoma (n = 11), which occurred within the first 5 years after the diagnosis of ESCC, as potential LSPTs
b99% confidence interval